We concluded that the CD39+PD1+ fraction is enriched for large and convergent T cell clones that are involved in an ongoing tumor-specific immune response, a substantial portion of which are detectable via cluster TCR analysis. The gene discussed is PDCD1; the disease is neoplasm.